Welcome to our dedicated page for Biocardia news (Ticker: BCDA), a resource for investors and traders seeking the latest updates and insights on Biocardia stock.
Overview
BioCardia, Inc. (Nasdaq: BCDA) is a clinical‐stage regenerative medicine company dedicated to advancing cellular and cell‐derived therapeutics for cardiovascular and pulmonary diseases with significant unmet medical needs. Leveraging cutting‑edge stem cell technologies, the company is focused on developing innovative therapies through its proprietary CardiAMP autologous and CardiALLO allogeneic platforms. These biotherapeutic solutions are designed to address conditions such as ischemic heart failure and refractory angina, using state‑of‑the‑art delivery systems and precision medicine approaches.
Core Business and Technology
At the heart of BioCardia’s operations is its development of novel cell therapies that utilize the patient’s own marrow‐derived cells or allogeneic mesenchymal stem cells. Its pioneering therapeutic solutions are enabled by advanced delivery systems including the Helix™ biotherapeutic delivery platform and the Morph® vascular navigation system. These systems not only improve the safety and efficacy of cell delivery through minimally invasive catheter‑based procedures, but also ensure enhanced cell retention and precise dosing.
Clinical Development and Value Proposition
BioCardia is progressing multiple clinical-stage product candidates through rigorous, randomized controlled trials. Its CardiAMP cell therapy has garnered significant regulatory recognition, including breakthrough designations from the FDA, underscoring its potential to improve survival rates, reduce major adverse cardiac events, and enhance overall quality of life. The company’s approach features a personalized treatment strategy that incorporates pre‑procedural cell population analysis for optimal patient selection and dosing, thereby maximizing therapeutic benefit.
Market Position and Competitive Landscape
Positioned within the competitive landscape of biointerventional cardiology and regenerative medicine, BioCardia distinguishes itself through its robust intellectual property portfolio and innovative therapeutic modalities. The company’s comprehensive range of technologies supports a variety of cardiovascular interventions, setting it apart from peers by addressing multiple clinical indications with both autologous and off‑the‑shelf solutions. This diversification helps the company meet a broad spectrum of clinical needs, ensuring a solid foundation within its niche market segment.
Operational Insights and Technological Advancements
BioCardia’s operational model emphasizes efficiency, low operational cash burn, and strategic collaboration with leading clinical and research institutions. The development of the Morph® DNA™ steerable introducers—characterized by bidirectional steering, precise torque response, and innovative design elements—illustrates the company’s commitment to technological advancement. These devices enable smoother navigation through the complex vasculature and minimize procedural complications, thereby contributing to superior patient outcomes during minimally invasive interventions.
Industry Relevance and Conclusion
For investors, analysts, and healthcare professionals, BioCardia represents an intersection of advanced regenerative medicine and precision interventional cardiology. Its focused approach on cellular therapeutics, combined with a well‑defined delivery system and supportive clinical data, provides a clear understanding of its role in addressing unmet clinical needs. BioCardia, Inc. maintains a deep commitment to improving patient care through innovative biotherapeutic solutions, supported by a rigorous clinical development process and strategic technological partnerships.
BioCardia (NASDAQ: BCDA), a leader in cardiovascular and pulmonary disease therapeutics, has announced a correction to their conference call timing for discussing two-year CardiAMP-HF results. The call is scheduled for March 31, 2025, at 4:30 PM EDT, not PDT as previously stated.
U.S. participants can call 1-833-316-0559, while international callers should dial 1-412-317-5730. Pre-registration is available at dpregister.com/sreg/10194429/fdf5f0e427. A live webcast will be accessible through event.choruscall.com, with replay options available approximately one hour after the call concludes.
BioCardia (NASDAQ: BCDA) announced two-year outcomes from its Phase 3 CardiAMP-HF study, evaluating CardiAMP autologous cell therapy for ischemic heart failure patients with reduced ejection fraction. The trial, involving 115 patients across 18 centers in the US and Canada, showed promising results.
In patients with elevated NTproBNP biomarkers (50% of enrolled patients), the therapy demonstrated:
- 13% fewer heart death equivalents with 47% relative risk reduction
- 2% fewer non-fatal major adverse cardiac events with 16% risk reduction
- 10.5-point improvement in quality-of-life scores
Overall results showed 3.6% fewer heart death equivalents, 8.7% fewer non-fatal adverse events, and meaningful quality of life improvements. The FDA-designated Breakthrough Therapy incorporates three proprietary elements: pre-procedural cell analysis, high target cell dosage, and a minimally-invasive delivery system.
BioCardia (NASDAQ: BCDA) has reported its financial results for 2024, showing a reduced net loss of $7.9 million compared to $11.6 million in 2023. The company's net cash used in operations decreased to $8.0 million from $10.0 million in 2023.
Key financial metrics include:
- Cash and cash equivalents: $2.4 million at year-end
- Revenues: $58,000 (down from $477,000 in 2023)
- R&D expenses: $4.4 million (decreased from $7.7 million)
- SG&A expenses: $3.7 million (reduced from $4.4 million)
Notable developments include completion of the CardiAMP HF Trial's last protocol-specified follow-up visit, with results to be presented at the ACC Scientific Sessions. The company has also completed treatment of the low-dose cohort in the CardiALLO Cell Therapy trial and launched commercial Morph DNA steerable introducer devices. Japan's PMDA has shown openness to considering existing trial results for potential product registration.
BioCardia (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has scheduled key events for March 2025. The company will release its 2024 financial results on March 26, 2025, followed by a corporate update conference call on March 31, 2025.
Additionally, BioCardia will present the principal results of the CardiAMP-HF Trial at the American College of Cardiology 2025 Scientific Sessions in Chicago on March 30, 2025. The presentation will focus on 'A Double-blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF'.
BioCardia (BCDA) has been granted Japanese Patent No. 7641330 for its Helix™ Biotherapeutic Delivery System, extending protection until at least September 30, 2034. The patent covers minimally invasive catheter-based delivery systems for cell and gene-based therapies to the heart.
The Helix System, featuring helical needle-tipped catheter technology, is currently the only catheter-based intramyocardial delivery system in active clinical use. The technology enables targeted treatment while minimizing off-target toxicities and avoiding surgical heart access.
Japan represents a strategic market for these therapies due to its national commitment to supporting novel cell therapy solutions for its aging population while developing its stem cell industry.
BioCardia (BCDA) has completed data verification for its Phase 3 CardiAMP HF study, a double-blind randomized placebo-controlled trial evaluating an autologous cell therapy for ischemic heart failure. The study, involving 115 randomized patients, represents the largest cohort of ischemic HFrEF patients in a randomized autologous cell therapy trial.
The trial data has been transferred to the Statistical Data Analysis Center for analysis, with results scheduled for presentation at the Late-Breaking Clinical Trials symposium at the American College of Cardiology 2025 Scientific Sessions on March 30, 2025. The study is notable for using a precision medicine approach to identify potential responders based on cell characteristics.
The trial aims to demonstrate therapeutic benefit for HFrEF patients with elevated NT-proBNP who haven't responded sufficiently to medication. Results will support regulatory approvals in the US and Japan for both the CardiAMP cell therapy system and the Helix biotherapeutic delivery system.
BioCardia (NASDAQ: BCDA) has completed enrollment and dosing in the low dose cohort of its CardiALLO™ Allogeneic Mesenchymal Cell Therapy Phase I/II trial. The study targets patients with ischemic heart failure of reduced ejection fraction (HFrEF) who have elevated markers of heart stress and systemic inflammation.
The trial consists of a Phase I nine-patient dose escalation cohort, followed by a thirty-patient randomized double-blinded placebo procedure-controlled cohort. The Phase I study will test three escalating doses: 20 million, 100 million, and 200 million cells, using BioCardia's minimally invasive delivery system. The first Data Safety Monitoring Board review is expected in March 2025.
The therapy utilizes 'off the shelf' mesenchymal stem cells, manufactured at BioCardia's Sunnyvale facility, and is delivered using the FDA-approved Morph DNA steerable guide. The treatment aims to provide immunomodulatory benefits and enhance microvascular repair in heart failure patients.
BioCardia (NASDAQ: BCDA) has announced that its CardiAMP HF Phase 3 study results will be presented at the American College of Cardiology 2025 Scientific Sessions in Chicago, March 29-31, 2025. The presentation, featuring results from the double-blind randomized placebo-controlled trial investigating an autologous cell therapy in patients with HFrEF, will be delivered by Dr. Amish N. Raval from the University of Wisconsin at Madison.
The presentation is scheduled for March 30, 2025, at 3:30 PM in the Main Tent as part of the Featured Clinical Research II session. The American College of Cardiology Scientific Sessions is a prominent forum for cardiovascular clinical trial developments, attracting experts from medical, pharmaceutical, biotechnology, and medical device sectors.
BioCardia (NASDAQ: BCDA) has announced the commercial launch of its Morph DNA steerable introducer product family, which is currently being used in the company's ongoing cell-therapy clinical trials. The company is pursuing an organic sales approach without engaging a direct sales force or third-party partners to minimize operating costs.
The company maintains its focus on the CardiAMP Heart Failure I and II clinical trials, which are studying their FDA-designated breakthrough cell therapy product for ischemic heart failure treatment. Final results for CardiAMP Heart Failure I Trial and updates on five actively enrolling centers in the CardiAMP Heart Failure II Trial are expected by the end of Q1 2025.
BioCardia (Nasdaq: BCDA) announced a successful consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) regarding its lead therapeutic asset, BCDA-01, for treating ischemic heart failure. The PMDA has invited BioCardia for a follow-up consultation after reviewing final clinical data with two-year follow-up from the CardiAMP Heart Failure Trial.
The agency indicated openness to considering results from the CardiAMP Heart Failure Trial and previous trials as sufficient evidence for registering the CardiAMP Cell Therapy System in Japan. The company expects final data from its fully enrolled 125-patient trial to be available in Q1 2025. The therapy has received FDA Breakthrough Designation and is supported by the Maryland Stem Cell Research Fund and CMS reimbursement.
FAQ
What is the current stock price of Biocardia (BCDA)?
What is the market cap of Biocardia (BCDA)?
What is the primary focus of BioCardia Inc?
Which therapeutic platforms does BioCardia utilize?
How does BioCardia's delivery technology work?
What distinguishes BioCardia in the competitive landscape?
What clinical indications are being addressed by BioCardia's therapies?
Has BioCardia received any regulatory recognition?
What role do the Morph® DNA™ steerable introducers play?
Does BioCardia collaborate with other institutions?
